What do systematic reviews say?

Lamotrigine vs valproate

The review found no eligible studies for this question.

• Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Add‐on lamotrigine vs placebo

Add‐on lamotrigine may leads to higher 50% or greater reduction in seizure frequency compared with placebo (low certainty).

• Lamotrigine add‐on therapy for drug‐resistant generalised tonic‐clonic seizures 2020 · Cochrane Headline outcomes only
  RR 1.88 [1.43, 2.45]
  2 studies · 270 participants
  Low

Lamotrigine vs placebo

Summary of findings: lamotrigine probably leads to higher 50% or greater reduction in seizure frequency (ITT analysis) compared with placebo (moderate certainty).

• Lamotrigine add‐on therapy for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
  RR 1.8 [1.45, 2.23]
  12 studies · 1322 participants
  Moderate

Ethosuximide vs lamotrigine

The review found no eligible studies for this question.

• Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Ethosuximide vs valproate

• Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 49 participants
  Low